Researchers at Birmingham University have developed an eye drop that could treat wet AMD.

Why hasn’t this been done yet?
Because getting large drug molecules (i.e Lucentis & Avastin) all the way to the back of the eye is a challenge. Given the many layers of the cornea, the conjunctiva, the sclera, the blood-retinal barrier, drop dilution from tears….you could say there are a few obstacles to drug penetration.

So how did they do it?
CPP = cell penetrating peptides.
Through the magic of biochemistry, scientists found that attaching CPP within a drop aids in drug delivery.

What did the study find?
Their anti-VEGF drop with CPP (dosed daily) was just a efficacious as a single intravitreal injection in reducing areas of CNV in mouse, rat, and pig eyes.
The authors state, “Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments”.
(via)

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.

Related Articles

Latest Posts